SCLN: Summary for SciClone Pharmaceuticals, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 8:00am EST - Canadian Markets open in 1 hour and 30 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

SciClone Pharmaceuticals, Inc. (SCLN)

On Feb 9: 2.57 USD 0.00 (0.00%)

MORE ON SCLN

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

SciClone Pharmaceuticals, Inc. (NGM:SCLN) Delayed quote data

Last Trade:	2.57 USD
Trade Time:	Feb 9
Change:	0.00 (0.00%)
Prev Close:	2.57
Open:	N/A
Bid:	0.52 x 2000
Ask:	2.84 x 400
1y Target Est:	5.06

Day's Range:	N/A - N/A
52wk Range:	0.92 - 5.33
Volume:	0
Avg Vol (3m):	346,262
Market Cap:	121.31M
P/E (ttm):	18.90
EPS (ttm):	0.14
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Add SCLN to Portfolio

Download Data

HEADLINES

•	A Triple in the Making
	at Motley Fool (Mon, Feb 8)

•	E*Trade, Hanmi Financial: Early Volume Plays
	at TheStreet.com (Mon, Feb 8)

•	SciClone drug sustains swine flu shot in study
	AP (Mon, Feb 8)

•	SciClone and Sigma-Tau Announce Additional Positive Results in Clinical Study Examining ZADAXIN's Ability to Enhance Response to H1N1 Vaccine
	Marketwire (Mon, Feb 8)

•	SciClone Pharmaceuticals to Present at BIO CEO & Investor Conference
	Marketwire (Tue, Feb 2)

•	4 Stocks That Laugh at Wall Street
	at Motley Fool (Thu, Jan 28)

•	[video] Stocks Under $10: 2 Hot Biotech Names
	at TheStreet.com (Sun, Jan 17)

•	[video] Stocks Under $10: Two Hot Biotech Names
	at TheStreet.com (Sun, Jan 17)

•	SciClone says drug boosts H1N1 defense
	at bizjournals.com (Tue, Jan 12)

•	[video] Stocks Under $10: 2 Hot Biotech Names
	at TheStreet.com (Tue, Jan 12)

More Headlines for SCLN...

ANALYST

EPS Est (next year) (Dec-09) :	0.22
EPS Est (in 2 years) (Dec-10) :	0.23
Avg Rec (current)*:	1.7
PEG Ratio:	0.65

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

SciClone Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cancer and infectious diseases in China and internationally.

Full Company Profile

Add to Portfolio

Email to a Friend

•